First and second trimester antenatal screening for Down's syndrome: The results of the serum, urine and ultrasound screening study (SURUSS)

Health Technology Assessment

Volumn 7, Issue 11, 2003, Pages

  Wald, N J ^a   Rodeck, C ^b   Hackshaw, A K ^a   Walters, J ^a   Chitty, L ^b   Mackinson, A M ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BETA CORE FRAGMENT; BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRIOL; INHIBIN A; INVASIVE TROPHOBLAST ANTIGEN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; UNCLASSIFIED DRUG;

ADULT; AMNIOCENTESIS; ARTICLE; BLOOD SAMPLING; CHORION VILLUS SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROWN RUMP LENGTH; DIAGNOSTIC TEST; DOWN SYNDROME; ESTRIOL BLOOD LEVEL; FEMALE; FETUS ECHOGRAPHY; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GESTATIONAL AGE; GONADOTROPIN BLOOD LEVEL; HEALTH CARE COST; HORMONE BLOOD LEVEL; HORMONE URINE LEVEL; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL SERUM; OUTCOMES RESEARCH; PERFORMANCE; PRENATAL CARE; PRENATAL SCREENING; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SAFETY; SECOND TRIMESTER PREGNANCY; ULTRASOUND; URINALYSIS; AUSTRIA; BLOOD; ECHOGRAPHY; ECONOMICS; METABOLISM; METHODOLOGY; MULTICENTER STUDY; PREGNANCY; PRENATAL DIAGNOSIS; UNITED KINGDOM; URINE;

ADULT; ALPHA-FETOPROTEINS; AUSTRIA; CHORIONIC GONADOTROPIN; DOWN SYNDROME; FEMALE; GREAT BRITAIN; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS;

EID: 85045797401     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta7110     Document Type: Article

References (50)

1. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297:883-7.
2. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997;4:181-247.
3. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. N Engl J Med 1999;341:461-7.
4. Cuckle HS, Canick JA, Kellner LH on behalf of the Collaborative Study Group. Collaborative study of maternal urine β-core hCG screening for Down syndrome. Prenat Diagn 1999;19:911-17.
5. Cole LA, Shahabi S, Oz UA, Bahado-Singh RO, Mahoney MJ. Hyperglycosylated hCG (invasive trophoblasts antigen) immunoassay: A new basis for gestational Down syndrome screening. Clin Chem 1999;45:2109-19.
6. Wald NJ, Cuckle HS, Densem J W, Kennard A, Smith D. Maternal serum screening for Down's syndrome: The effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight. Brit J Obstet Gynaecol 1992;99:144-9.
7. Morris JK, Mutton DE, Albermann E. Revised estimates of maternal age specific live birth prevalence of Down's syndrome in the absence of antenatal screening and selective termination. J Med Screen 2002;9:2-6.
8. Wald N, Hackshaw A. Tests using multiple markers. In: Wald NJ, Leck I, editors. Antenatal and Neonatal Screening, 2nd ed., Oxford: Oxford University Press; p. 23-57.
9. Office for National Statistics. Birth Statistics. England and Wales; 1996, 1997, 1998 (FMI, Nos 25-27). London: The Stationery Office; 1998.
10. Royston P, Thompson SG. Model-based screening by risk with application to Down's syndrome. Stat Med 1992;11:257-68.
11. Morris JK, Wald NJ, Watt HC. Fetal loss in Down syndrome pregnancies. Prenat Diagn 1999;19:142-5.
12. Gosden C, Tabor A, Leck IL, Grant A, Alfirevic A, Wald N. Amniocentesis and chorionic villus sampling. In: Wald NJ, Leck I, editors. Antenatal and Neonatal Screening, 2nd ed., Oxford: Oxford University Press; 2000. p. 470-516.
13. Gilbert RE, Augood C, Gupta R, Ades AE, Logan S, Sculpher M, et al. Screening for Down's syndrome: Effects, safety, and cost effectiveness of first and second trimester strategies. BMJ 2001;323:423-5.
14. Nicolaides KH, Snijders KM, Cuckle HS. Correct estimation of parameters for ultrasound translucency screening. Prenat Diagn 1998;18:519-21.
15. Hyett JA, Sebire NJ, Snijders, Nicolaides KH. Intrauterine lethality of trisomy 21 fetuses with increased nuchal translucency thickness. Ultrasound Obstet Gynecol 1996;7:101-3.
16. Grudzinskas JG. Endocrinological and metabolic assessment of early pregnancy. In: Chamberlain G, editor. Turnbull's Obstetrics. 2nd ed., Edinburgh: Churchill Livingstone; 1995. p. 185-93.
17. Macri J, Kasturi RV, Krantz BS, Cook EJ, Moore ND, Young JA, et al. Maternal serum Down syndrome screening: Free β-protein is a more effective marker than human chorionic gonadotropin. Am J Obstet Gynecol 1990;163:1248-53.
18. Cuckle HS, Holding S, Jones R, Groome NP, Wallace EM. Combining inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome. Prenat Diagn 1996;16:1095-100.
19. Aitken DA, Wallace EM, Crossley JA, Swanston IA, Van Parenen Y, Van Maarle M, et al. Dimeric inhibin-A as a marker for Down's syndrome in early pregnancy. N Engl J Med 1996;334:1231-6.
20. Forest JC, Masse J, Rousseau F, Moutquin JM, Brideau NA, Belanger M. Screening for Down's syndrome during the first and second trimesters: Impact of risk estimation parameters. Clin Biochem 1995;28:443-9.
21. Spencer K. Evaluation of an assay of the free b-subunit of choriogonadotropin and its potential value in screening for Down's syndrome. Clin Chem 1991;37:809-14.
22. Knight GJ, Palomaki GE, Neveux LM, Fodor KK, Haddow JE. hCG and the free b-subunit as screening tests for Down syndrome. Prenat Diagn 1998;18:235-45.
23. Wald NJ, Densem JW, Smith D, Klee GG. Four-marker serum screening for Down's syndrome. Prenat Diagn 1994;14:707-16.
24. Spencer K, Macri JN. Early detection of Down's syndrome using free beta human chorionic gonadotrophin. Ann Clin Biochem 1992;29:349-50.
25. Crossley JA, Aitken DA, Connor JM. Prenatal screening for chromosome abnormalities using maternal serum chorionic gonadotrophin, alpha-fetoprotein, and age. Prenat Diagn 1991;11:83-101.
26. Norgaard Pedersen B, Alfthan H, Arends J, Hogdall CK, Larsen SO, Petterson K, et al. A new simple and rapid dual assay for AFP and free β-hCG in screening for Down syndrome. Clin Genet 1994;45:1-4.
27. Ryall RG, Staples AJ, Robertson EF, Pollard AC. Improved performance in a prenatal screening programme for Down's syndrome incorporating serum-free-hCG subunit analyses. Prenat Diagn 1992;12:251-61.
28. Macri JN, Anderson RW, Krantz DA, Larsen JW, Buchanan PD. Prenatal maternal dried blood screening with AFP and free β-hCG for open neural tube defects and Down's syndrome. Am J Obstet Gynecol 1996;174:566-72.
29. Wenstrom KD, Owen J, Chu DG, Boots L. Free β-hCG subunit versus intact hCG in Down's syndrome screening. Obstet Gynecol 1997;90:370-4.
30. Spencer K, Coombes EJ, Mallard AS, Milford-Ward A. Free beta human choriogonadotropin in Down's syndrome screening: A multicentre study of its role compared with other biochemical markers. Ann Clin Biochem 1992;29:506-18.
31. Stone S, Henley R, Reynolds T, John R. A comparison of total and free β-subunit assays in Down syndrome screening. Prenat Diagn 1993;13:535-7.
32. Spencer K. Second trimester prenatal screening for Down's syndrome using AFP and free β-hCG: A 7 year review. Br J Obstet Gynecol 1999;106:1287-93.
33. Macri JN, Spencer K, Anderson R. Dual analyte immunoassay - A new approach to neural tube defect and Down syndrome screening. Ann Clin Biochem 1992;29:390-6.
34. Hsu JJ, Hsieh TT, Soong YK, Spencer K. Comparison of Down's syndrome screening strategies in Asians. Combining serum free β-hCG and AFP with maternal age. Prenat Diagn 1997;17:707-16.
35. Chao AS, Chung CL, Wu CD, Chang SD, Cheng PJ, Lin YT, et al. Second trimester maternal serum screening using AFP, free β-hCG and maternal age. Result of chromosomal abnormalities detected in screen positive for Down syndrome in an Asian population. Acta Obstet Gynecol Scand 1999;78:393-7.
36. Macri JN, Anderson RW, Kasturi RV, Krantz DA, Cook EJ. Enhanced Down syndrome detection with free beta (hCG). Am J Hum Genet 1992;51:A418.
37. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening programme for trisomy 21 at 10-14 weeks using fetal NT, maternal serum free β-hCG and PAPP-A. Ultrasound Obstet Gynecol 1999;13:231-7.
38. Wald NJ, Hackshaw AK, George LM. Assay precision of serum (a fetoprotein in antenatal screening for neural tube defects and Down's syndrome. J Med Screen 2000;7:74-7.
39. Wald NJ, George L, Smith D, Densem JW, Petterson K Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. Br J Obstet Gynaecol 1996;103:407-12.
40. Cicero S, Curcio P, Papageorghiou A, Sanek J, Nicolaides K. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: An observational study. Lancet 2001;358:1665-7.
41. De Biasio P, Venturini PL. Absence of nasal bone and detection of trisomy 21. Lancet 2002;359:1344.
42. Ward BE, Gersen SL, Carelli MP, McGuire NM, Dackowski WR, Weinstein M, et al. Rapid prenatal diagnosis of chromosomal aneuploidies by fluorescence in situ hybridisation: Clinical experience with 4500 specimens. Am J Hum Genet 1993;52:854-65.
43. Levett IJ, Liddle S, Meredith R. A large scale evaluation of amnio-PCR for the rapid prenatal diagnosis of fetal trisomy. Ultrasound Obstet Gynecol 2001;17:115-18.
44. Mann K, Fox SP, Abbs SJ, Yau SC, Scriven PN, Docherty Z, et al. Development and implementation of a new rapid aneuploidy diagnostic service within the UK National Health Service and implications for the future of prenatal diagnosis. Lancet 2001;358:1057-61.
45. Lawson HW, Frye A, Altrash HK, Smith JC, Shilman HB, Ramick M. Obstetrics: Abortion mortality, United States, 1972 through 1987. Am J Obstet Gynecol 1994;171:1365-72.
46. Chitty L, Statham H, Sololou W, Green J. Grief after termination for fetal abnormality - Is there a gestational age effect? Ultrasound Obstet Gynecol 1998;12 Suppl 1:3.
47. Bischoff FZ, Lewis D, Simpson JL, Nguyen DD, Marquez-Do D, Bryson A, et al. Isolating fetal cells from maternal blood: Strategies to increase sensitivity for fetal aneuploidy detection. Am J Hum Genet 1999;65 Suppl:A943.
48. Bianchi DW, Simpson JL, Jackson LG, Elias S, Holzgreve W, Evans MI, et al. Fetal gender and aneuploidy detection using fetal cells in maternal blood: Analysis of NIFTY I data. Prenat Diagn 2002;22:609-15.
49. Holzgreve W. Prenatal diagnosis using fetal cells and free fetal DNA in maternal blood. Clin Perinatol 2001;28:353-65.
50. Wald N, Huttly W, Hackshaw A. Antenatal screening for Down's syndrome with the quadruple test: 5 year results from a screening programme. Lancet 2003;361:835-6.